Upper-body obesity, especially when associated with visceral fat accumulation, is related to the development of metabolic abnormalities, such as insulin resistance, type 2 diabetes, and dyslipidemia ([@B1],[@B2]). In contrast, lower-body obesity does not exhibit these abnormalities ([@B3],[@B4]). The mechanism behind the development of these different obesity phenotypes remains unclear ([@B5],[@B6]). Studies have not provided clear evidence to suggest that differences in regional lipolysis promote the development of differences in adipose tissue distribution ([@B6]--[@B8]). Moreover, studies of meal fat storage and direct plasma free fatty acid (FFA) storage have failed to demonstrate definite differences, with reports showing greater ([@B9],[@B10]) and similar ([@B6],[@B11]) storage in visceral compared with subcutaneous adipose tissue in lean and obese men and women.

Differences between chylomicron and VLDL-triglyceride (VLDL-TG) uptake in different regional adipose tissues ([@B12]) underscore that studies of VLDL-TG storage are warranted. By using an ex vivo--labeled VLDL-TG tracer, we recently reported that VLDL-TG adipose tissue fatty acid storage was similar in upper-body subcutaneous (UBSQ) and lower-body subcutaneous (LBSQ) fat in lean and obese women ([@B13]) and in obese and type 2 diabetic men ([@B14]). Thus far, no studies have investigated VLDL-TG fatty acid storage in visceral adipose tissue.

The aim of this study was to test the hypothesis that VLDL-TG fatty acid storage is greater in visceral adipose tissue compared with LBSQ and UBSQ adipose tissue. We wanted to test this hypothesis in both upper-body obese (UBO) and lean women. A secondary aim was to assess whether the storage pattern differed between UBO and lean women.

RESEARCH DESIGN AND METHODS {#s5}
===========================

The protocol was approved by the local ethics committee, and informed consent was obtained from all participants. Nine UBO women (waist circumference \>88 cm) and 6 lean women (waist circumference \<80 cm) scheduled for voluntary laparoscopic tubal occlusion were recruited. All were nonsmokers, used no medication except oral contraceptives, and had a normal blood and chemistry panel. One week before the study day, a blood sample for VLDL-TG tracer preparation was obtained after a 10--14 h overnight fast. Dual X-ray absorptiometry scan and abdominal computed tomography scan at the L~2~-L~3~ interspace were performed to obtain anthropometric indices ([@B15]).

Protocol. {#s6}
---------

[Figure 1](#F1){ref-type="fig"} illustrates the study protocol. Participants were admitted to the Elective Surgery Section on the day of the procedure at 0745 h (*t* = −15 min) after a 10--14 h overnight fast. A catheter was placed in an antecubital vein, and at 0800 h (*t* = 0 min) a bolus of \[9,10-^3^H\]VLDL-TG was infused. At *t* = 165 min, the participant was taken to the operating room and anesthetized. A biopsy from omental fat was obtained immediately after the tubal occlusion procedure (*t* = ∼190 min). Immediately after the laparoscopic procedure, biopsies were obtained from UBSQ and LBSQ adipose tissue (*t* = ∼200 min). After blood sampling at 210 min, the participants were awakened from anesthesia and followed a normal postoperative procedure.

![Study protocol.](2787fig1){#F1}

### VLDL-TG tracer preparation. {#s7}

A 60-mL blood sample was obtained under sterile conditions from each volunteer. Plasma VLDL-TG was labeled with 120 μCi of \[9,10-^3^H\]triolein (Perkin Elmer, Inc., Waltham, MA) as previously described ([@B16]).

### Plasma VLDL-TG concentration and specific activity. {#s8}

VLDL-TG concentration and specific activity (SA) were measured after ultracentrifugation as previously described ([@B16]).

### Adipose tissue biopsies. {#s9}

Omental adipose tissue biopsies were obtained from the middle of the lower edge of the omentum. The UBSQ and LBSQ adipose tissue biopsies were obtained using a liposuction technique from the periumbilical and anterior femoral regions.

### Adipose tissue ^3^H-TG SA and fat cell size. {#s10}

Adipose tissue lipid SA (dpm/g) was measured after lipid extraction from adipose tissue biopsies, as described previously ([@B17]). Fat cell size was determined immediately after the biopsy procedure, as described previously ([@B18]).

### Calculations. {#s11}

VLDL-TG secretion rate was calculated using a bi-exponential fit to the plasma tracer decay curve with correction ([@B19]). VLDL-TG FA storage was calculated both as a timed storage rate (μmol/min) and as the net fraction stored over the 210 min in the entire depot, per kilogram lipid, and per 10^6^ fat cells. The VLDL-TG storage rate into adipose tissue (μmol/min) was calculated as the fractional tracer storage × VLDL secretion rate.

### Statistics. {#s12}

Data are presented as mean ± SD or median (range) as appropriate. Differences between groups were evaluated using the Student *t* test or Mann--Whitney test. Analyses of differences in regional storage were performed using repeated-measurement ANOVA with post hoc comparison using the Student *t* test for paired samples. Correlations are Pearson *r*. Statistical significance was set at *P* = 0.05.

RESULTS {#s13}
=======

Baseline data are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of participants

                               UBO women        Lean women       *P* value
  ---------------------------- ---------------- ---------------- -----------
  *n*                          9                6                
  Age (years)                  35 (28--40)      41 (33--43)      \<0.05
  Weight (kg)                  82.7 ± 5.0       65.2 ± 4.9       \<0.01
  BMI (kg/m^2^)                30.1 ± 4.0       23.5 ± 1.3       \<0.01
  Waist-to-hip ratio           0.86 ± 0.04      0.80 ± 0.05      \<0.05
  Fat free mass (kg)           51.9 ± 3.5       45.6 ± 4.2       \<0.01
  Total fat mass (kg)          30.8 ± 4.2       19.6 ± 3.5       \<0.01
  Fat (%)                      37.2 ± 3.8       30.0 ± 4.6       \<0.05
  Visceral fat (kg)            1.9 ± 0.6        1.0 ± 0.5        \<0.05
  UBSC fat (kg)                14.5 ± 3.0       8.4 ± 2.3        \<0.01
  LBSC fat (kg)                14.4 ± 1.4       10.1 ± 1.3       \<0.01
  TG (mmol/L)                  1.2 (0.9--1.6)   0.9 (0.8--1.2)   0.37
  Total cholesterol (mmol/L)   4.8 ± 0.7        4.3 ± 0.8        0.21
  LDL cholesterol (mmol/L)     2.4 ± 0.7        2.6 ± 0.6        0.71
  HDL cholesterol (mmol/L)     1.4 ± 0.3        1.9 ± 0.2        \<0.01
  FFA (mmol/L)                 0.59 ± 0.31      0.47 ± 0.14      0.38
  Insulin (pmol/L)             48.6 ± 24.6      27.6 ± 11.5      0.08
  HOMA-IR                      1.83 ± 0.98      0.93 ± 0.40      \<0.05

Data are mean ± SD or median (range). HOMA-IR, homeostasis model assessment of insulin resistance.

VLDL-TG turnover. {#s14}
-----------------

VLDL-TG secretion rates (52 ± 12 vs. 46 ± 11 μmol/min; not significant) and VLDL clearance rates (43 ± 13 vs. 50 ± 15 mL/min) were similar in UBO and lean women. At 210 min, the residual amount of \[9,10-^3^H\]VLDL-TG in plasma was low in both groups (3.6 ± 2.0 vs. 2.2 ± 0.5%; not significant).

VLDL-TG storage. {#s15}
----------------

To explore the possibility of adipose tissue sample contamination by residual activity from plasma ([@B20]), residual plasma activity was plotted against activity in adipose tissue samples (dpm/g). No sign of a relationship was detected in any of the regional depots. VLDL-TG fractional storage was equivalent in UBO and lean women in each of the regional depots (visceral fat: 0.76 ± 0.48 vs. 0.81 ± 0.60%, not significant; UBSQ fat: 4.4 ± 2.9 vs. 5.7 ± 4.7%, not significant; LBSQ fat: 4.8 ± 2.8 vs. 3.9 ± 1.0%, not significant) ([Fig. 2*A*](#F2){ref-type="fig"}). VLDL-TG storage rates in each of the different regional fat depots were also equivalent in UBO and lean women (visceral fat: 0.42 ± 0.29 vs. 0.35 ± 0.23 μmol/min, not significant; UBSQ fat: 2.3 ± 1.5 vs. 2.7 ± 2.7 μmol/min, not significant; LBSQ fat: 2.7 ± 1.9 vs. 1.8 ± 0.7 μmol/min, not significant) ([Fig. 2*B*](#F2){ref-type="fig"}). As expected, because of lower visceral fat depot size, both fractional storage and storage rates were significantly lower in visceral fat compared with both LBSQ and UBSQ fat for both UBO and lean women (all *P* \< 0.05).

![*A*: VLDL-TG fractional storage in visceral, UBSQ, and LBSQ fat. *B*: VLDL-TG storage rate in visceral, UBSQ, and LBSQ fat. *C*: Fractional VLDL-TG storage per kilogram lipid in visceral, UBSQ, and LBSQ fat. *D*: Fractional VLDL-TG storage per 10^6^ fat cells in visceral, UBSQ, and LBSQ fat. Error bars are SEM. \**P* \< 0.05 compared with visceral fat within group. †*P* \< 0.05 between UBO and lean women.](2787fig2){#F2}

The fraction of VLDL-TG storage per kilogram lipid ([Fig. 2*C*](#F2){ref-type="fig"}) was significantly lower in UBSQ fat in UBO compared with lean women (*P* = 0.04). No significant differences were observed in the fractional VLDL-TG storage per kilogram lipid among visceral, UBSQ, and LBSQ fat depots in UBO or lean women. The fraction of VLDL-TG storage per 10^6^ fat cells ([Fig. 2*D*](#F2){ref-type="fig"}) displayed the same pattern as storage per kilogram lipid; however, no significant differences were observed between different regional adipose tissue depots or between groups.

VLDL-TG storage and regional fat mass. {#s16}
--------------------------------------

There was no significant correlation between fractional VLDL-TG storage per kilogram lipid and fat mass in visceral fat, UBSQ fat, or LBSQ fat. Fractional VLDL-TG storage per 10^6^ fat cells was significantly associated with UBSQ fat mass in lean women (*r* = 0.82, *P* \< 0.05). A similar relationship was observed in UBO women, although it was not significant (*r* = 0.66, *P* = 0.08). No significant correlations were observed with visceral or LBSQ fat.

VLDL-TG storage and VLDL-TG concentration and secretion. {#s17}
--------------------------------------------------------

In lean women, fractional VLDL-TG storage in visceral (*r* = −0.89, *P* = 0.02) and LBSQ (*r* = −0.87, *P* = 0.02) fat was inversely associated with VLDL-TG concentration ([Fig. 3*A*--*C*](#F3){ref-type="fig"}). In UBSQ fat, a similar but not significant relationship was observed ([Fig. 3*B*](#F3){ref-type="fig"}). In UBO women, a tendency toward a positive relationship was observed between fractional VLDL-TG storage and VLDL-TG concentration in all regional fat depots, although only significant in UBSQ fat (*r* = 0.68, *P* = 0.04) ([Fig. 3](#F3){ref-type="fig"}). No significant correlations were observed between fractional VLDL-TG storage and VLDL-TG secretion in any of the regional depots in UBO and lean women.

![Fractional VLDL-TG storage vs. VLDL-TG concentration. *A*: Visceral fat. *B*: UBSQ fat. *C*: LBSQ fat. ● = UBO, ○ = lean, \**P* \< 0.05.](2787fig3){#F3}

DISCUSSION {#s18}
==========

This study is the first to compare direct quantitative VLDL-TG storage in visceral, UBSQ, and LBSQ fat in lean and UBO women, and the data reveal several novel results. The main findings are that visceral fat storage per kilogram lipid is equivalent to that of UBSQ and LBSQ, and therefore contributes quantitatively less to overall postabsorptive VLDL-TG storage. In addition, trafficking of VLDL-TG fatty acids for storage into visceral fat, UBSQ, and LBSQ fat depots is similar in lean and UBO women. Moreover, VLDL-TG concentration correlates positively with VLDL-TG storage in UBO women, but inversely in lean women.

Visceral adipose tissue has attracted special interest because of the anatomic location with venous drainage into the portal circulation. However, studies of visceral fat storage and lipolysis are sparse and conflicting, probably because of the obvious limitations in the ability to obtain visceral fat biopsies. In the current study, we used a newly developed tracer technique in combination with adipose tissue biopsies to measure VLDL-TG storage in visceral, UBSQ, and LBSQ adipose tissue. We hypothesized that visceral fat would be more metabolically active in comparison with subcutaneous fat with a greater storage efficiency to match the potential greater lipolysis. However, we found the VLDL-TG fatty acid storage per kilogram lipid to be similar in visceral, UBSQ, and LBSQ in both UBO and lean women. Therefore, because of the smaller size of the visceral fat depot compared with the UBSQ and LBSQ depots, the relative contribution of visceral fat to the overall VLDL-TG storage is significantly lower than storage in UBSQ and LBSQ fat. This finding corroborates with studies of meal fat ([@B11]) and direct plasma FFA storage ([@B6]) in women. However, in men, two studies reported increased storage of meal fatty acids ([@B10]) and plasma FFA ([@B9]) in visceral fat compared with UBSQ fat. This suggests sex-specific differences in visceral adipose tissue biology, resulting in more avid storage in visceral adipose tissue in men compared with women, and may help explain the more distinct UBO pattern typically seen in men.

No significant differences in VLDL-TG fractional storage, storage rate, and fractional storage per kilogram lipid were observed between the individual fat depots in both UBO and lean women, indicating a similar pattern in trafficking of VLDL-TG fatty acids. We take this as evidence against VLDL-TG storage as a prominent mechanism accounting for differences in body composition. In contrast, in a recent study of UBO and lean women, we found that fractional storage of VLDL-TG in UBSQ fat was greater in UBO compared with lean women ([@B21]). Differences in selection criteria of the obese subjects (BMI and waist-to-hip ratio as opposed to waist circumference) may partly explain this difference. Moreover, UBO women with greater body weight were included in our previous study ([@B21]), and the UBO women had higher VLDL-TG secretion rates compared with lean women, whereas VLDL-TG secretion rates were similar in the current study. These differences between the two studies could indicate that differences in VLDL-TG storage are not a cause of UBO but may instead be the consequence of more pronounced metabolic disturbances of UBO.

The relationship between fractional VLDL-TG storage and VLDL-TG concentration seemed opposite in UBO and lean women. The overall picture appeared the same in all three fat depots. We are not aware of previous studies reporting on the relationship between VLDL-TG storage and VLDL-TG plasma concentrations. The opposite relationships observed in the current study suggest that in lean women the ability of adipose tissue to store VLDL-TG predicts plasma concentration, i.e., lean women with high storage capacity have low VLDL-TG and vice versa. This is not the case for UBO women, in whom the storage capacity increases with greater VLDL-TG concentration, perhaps as an indication of compensatory mechanisms that upregulate VLDL-TG storage with progressively greater VLDL-TG concentrations. This supports previous reports of VLDL-TG concentration being predicted by VLDL-TG secretion rate in UBO women ([@B21]) as opposed to VLDL-TG clearance in lean women ([@B22]).

Some limitations are acknowledged. The sample size is small, which increases the risk of type 2 error. This could be important, because even small differences may play a role in long-term lipid redistribution. Moreover, subjects were examined before and during elective surgery, i.e., during a probable stress response, which may affect lipid metabolism; however, anesthesia was not initiated until after 165 min after the bolus infusion, allowing tracer to be stored for more than 2.5 h. Finally, visceral VLDL-TG tracer storage was extrapolated from small adipose tissue biopsies sampled from the omentum. However, omental fat has been shown to be a good surrogate for visceral fat ([@B23]).

In conclusion, VLDL-TG storage per kilogram lipid is similar in visceral, UBSQ, and LBSQ fat. Furthermore, there are no significant differences between UBO and lean women in the trafficking pattern of VLDL-TG into these adipose tissue depots. In addition, VLDL-TG concentration is differently related to the storage pattern in UBO and lean women. Postabsorptive VLDL-TG storage is unlikely to be of major importance in the development of preferential upper-body fat distribution in obese women.
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